0.0369
+0.0019
+(5.43%)
At close: April 8 at 5:24:40 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
757.1430
534.2690
2.4790
22.5950
30.1420
Cost of Revenue
392.2860
504.0980
577.4090
484.9010
119.9950
Gross Profit
364.8570
30.1710
-574.9300
-462.3060
-89.8530
Operating Expense
11,970.9310
12,345.7000
6,201.2930
7,428.4620
3,531.0260
Operating Income
-11,606.0740
-12,315.5290
-6,776.2230
-7,890.7680
-3,620.8790
Net Non Operating Interest Income Expense
-2,436.8250
3,185.9070
3,633.4940
-1,806.3530
-1,997.5530
Pretax Income
-36,477.9100
-9,620.2070
-4,345.9410
-12,478.3510
-6,684.1620
Tax Provision
-1,026.5220
-876.7570
-797.4400
-641.0490
-541.5010
Net Income Common Stockholders
-35,451.3910
-8,743.4500
-3,548.5030
-11,837.3020
-6,142.6610
Diluted NI Available to Com Stockholders
-35,451.3910
-8,743.4500
-3,548.5030
-11,837.3020
-6,142.6610
Basic EPS
-38.00k
-249.81k
-1.18M
-47.73k
-767.83k
Diluted EPS
-38.00k
-249.81k
-1.18M
-47.73k
-767.83k
Basic Average Shares
0.9330
0.0350
0.0030
0.2480
0.0080
Diluted Average Shares
0.9330
0.0350
0.0030
0.2480
0.0080
Total Operating Income as Reported
-6,793.8340
-6,907.5490
-6,444.9670
-7,827.8560
-3,491.7150
Total Expenses
12,363.2170
12,849.7980
6,778.7020
7,913.3630
3,651.0210
Net Income from Continuing & Discontinued Operation
-35,451.3910
-8,743.4500
-3,548.5030
-11,837.3020
-6,142.6610
Normalized Income
-13,784.0611
-8,424.9590
-2,619.1505
-9,198.9300
-5,163.2694
Interest Income
1,306.6280
1,306.8330
1,217.1680
45.1510
3.2910
Interest Expense
--
--
--
0.3640
0.8440
Net Interest Income
-2,436.8250
3,185.9070
3,633.4940
-1,806.3530
-1,997.5530
EBIT
-36,477.9100
-9,620.2070
-4,345.9410
-12,477.9870
-6,683.3180
EBITDA
-4,816.6760
-4,048.3170
-3,863.3890
-12,315.7010
-6,498.9770
Reconciled Cost of Revenue
392.2860
504.0980
577.4090
484.9010
119.9950
Reconciled Depreciation
31,661.2340
5,018.2920
466.9520
-8.6520
180.7130
Net Income from Continuing Operation Net Minority Interest
-35,451.3910
-8,743.4500
-3,548.5030
-11,837.3020
-6,142.6610
Total Unusual Items Excluding Goodwill
-22,294.7240
-350.4280
-1,138.2020
-2,781.2530
-1,065.7290
Total Unusual Items
-22,294.7240
-350.4280
-1,138.2020
-2,781.2530
-1,065.7290
Normalized EBITDA
17,478.0480
-3,697.8890
-2,725.1870
-9,534.4480
-5,433.2480
Tax Rate for Calcs
0
0.0001
0.0002
0.0001
0.0001
Tax Effect of Unusual Items
-627.3941
-31.9370
-208.8495
-142.8810
-86.3374
12/31/2020 - 4/21/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALGAE.PA FERMENTALG
0.3100
+4.38%
2HA.MU Spero Therapeutics Inc
0.5420
+4.43%
2GH.BE Merus NV
31.60
-7.06%
5KW.F SkinBioTherapeutics plc
0.2340
-14.60%
22Z.SG Zealand Pharma A/S
57.64
+8.26%
HQ1.MU Oruka Therapeutics Inc. R
7.10
-2.74%
05Y.F Vivoryon Therapeutics N.V.
1.8000
+5.88%
19KA.F CorMedix Inc.
5.55
+5.71%
HPHA.F Heidelberg Pharma AG
2.5100
+0.40%
SIGHT.PA GenSight Biologics S.A.
0.2330
+15.35%